Amirali Karimi1, Ali Nowroozi2, Sanam Alilou3, Erfan Amini4. 1. Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. karimi.amirali.1999@gmail.com. 2. Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. Nowrooziali77@gmail.com. 3. Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. Sanamalilouu@gmail.com. 4. Uro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. amini.erfan@gmail.com.
Abstract
PURPOSE: Transmembrane serine protease 2 (TMPRSS2) facilitates SARS-CoV-2 cellular entry. Androgens regulate this protein and may increase the risk of COVID-19. Therefore, androgen deprivation therapy (ADT) may protect patients with prostate cancer from SARS-CoV-2 infection or decrease the severity of the disease. Therefore, we conducted a meta-analysis to study the effect of androgen deprivation therapy (ADT) on COVID-19 in patients with prostate cancer. METHODS: We systematically searched PubMed, Embase, Scopus, and Cochrane databases. All records underwent a two-step screening process to identify the eligible studies. The registered PROSPERO number of this study was CRD42021228398. We evaluated the effect of ADT on the risk of infection, hospitalization, ICU admission, and mortality. RESULTS: Six studies met inclusion criteria and were evaluated in this study. We performed meta-analysis on four eligible studies. The overall incidence of COVID-19 was 2.65% among patients with prostate cancer receiving ADT. COVID-19 mortality rate was about 22.7% in ADT (+) patients. ADT did not decrease the risk of any of the major outcomes; infection risk (OR= 0.63, 95% CI= 0.27- 1.48, P = 0.29), hospitalization rate (OR= 0.51, 95% CI= 0.10- 2.53, P = 0.41), ICU admission (OR= 1.11, 95% CI= 0.43- 2.90, P = 0.82), and mortality risk (OR= 1.21, 95% CI= 0.34- 4.32, P = 0.77). CONCLUSION: We did not observe a protective effect on the risk of infection, hospitalization, ICU admission, and mortality in patients receiving ADT; therefore, it should not be considered as a prophylactic or treatment for COVID-19. On the other hand, ADT did not increase the mortality and morbidity of COVID-19 and should be considered a safe treatment for patients with prostate cancer during the pandemic. Further studies are necessary to confirm our findings.
PURPOSE: Transmembrane serine protease 2 (TMPRSS2) facilitates SARS-CoV-2 cellular entry. Androgens regulate this protein and may increase the risk of COVID-19. Therefore, androgen deprivation therapy (ADT) may protect patients with prostate cancer from SARS-CoV-2 infection or decrease the severity of the disease. Therefore, we conducted a meta-analysis to study the effect of androgen deprivation therapy (ADT) on COVID-19 in patients with prostate cancer. METHODS: We systematically searched PubMed, Embase, Scopus, and Cochrane databases. All records underwent a two-step screening process to identify the eligible studies. The registered PROSPERO number of this study was CRD42021228398. We evaluated the effect of ADT on the risk of infection, hospitalization, ICU admission, and mortality. RESULTS: Six studies met inclusion criteria and were evaluated in this study. We performed meta-analysis on four eligible studies. The overall incidence of COVID-19 was 2.65% among patients with prostate cancer receiving ADT. COVID-19 mortality rate was about 22.7% in ADT (+) patients. ADT did not decrease the risk of any of the major outcomes; infection risk (OR= 0.63, 95% CI= 0.27- 1.48, P = 0.29), hospitalization rate (OR= 0.51, 95% CI= 0.10- 2.53, P = 0.41), ICU admission (OR= 1.11, 95% CI= 0.43- 2.90, P = 0.82), and mortality risk (OR= 1.21, 95% CI= 0.34- 4.32, P = 0.77). CONCLUSION: We did not observe a protective effect on the risk of infection, hospitalization, ICU admission, and mortality in patients receiving ADT; therefore, it should not be considered as a prophylactic or treatment for COVID-19. On the other hand, ADT did not increase the mortality and morbidity of COVID-19 and should be considered a safe treatment for patients with prostate cancer during the pandemic. Further studies are necessary to confirm our findings.
Authors: Arielle Elkrief; Julie T Wu; Chinmay Jani; Kyle T Enriquez; Michael Glover; Mansi R Shah; Hira Ghazal Shaikh; Alicia Beeghly-Fadiel; Benjamin French; Sachin R Jhawar; Douglas B Johnson; Rana R McKay; Donna R Rivera; Daniel Y Reuben; Surbhi Shah; Stacey L Tinianov; Donald Cuong Vinh; Sanjay Mishra; Jeremy L Warner Journal: Cancer Discov Date: 2021-12-10 Impact factor: 38.272
Authors: Désirée van Deukeren; Berdine L Heesterman; Lianne Roelofs; Lambertus A Kiemeney; J Alfred Witjes; Tineke J Smilde; Geert J L H van Leenders; Luca Incrocci; Ben G L Vanneste; Richard P Meijer; Sabine Siesling; Bart P J van Bezooijen; Katja K H Aben Journal: Cancer Treat Res Commun Date: 2022-04-02
Authors: Karin Welén; Ebba Rosendal; Magnus Gisslén; Annasara Lenman; Eva Freyhult; Osvaldo Fonseca-Rodríguez; Daniel Bremell; Johan Stranne; Åse Östholm Balkhed; Katarina Niward; Johanna Repo; David Robinsson; Anna J Henningsson; Johan Styrke; Martin Angelin; Elisabeth Lindquist; Annika Allard; Miriam Becker; Stina Rudolfsson; Robert Buckland; Camilla Thellenberg Carlsson; Anders Bjartell; Anna C Nilsson; Clas Ahlm; Anne-Marie Fors Connolly; Anna K Överby; Andreas Josefsson Journal: Eur Urol Date: 2021-12-15 Impact factor: 20.096
Authors: Jim Q Ho; Mohammad Reza Sepand; Banafsheh Bigdelou; Tala Shekarian; Rahim Esfandyarpour; Prashant Chauhan; Vahid Serpooshan; Lalit K Beura; Gregor Hutter; Steven Zanganeh Journal: Immunology Date: 2022-05-03 Impact factor: 7.215